Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Gilead is to provide a $1.1 million annual donation to the Czech Republic's Institute of Organic Chemistry and Biochemistry for an initial five-year term to fund the establishment of a Gilead Sciences Research Centre.
Subscribe to our email newsletter
The Institute of Organic Chemistry and Biochemistry (IOCB) will use the donations to establish and support the Gilead Sciences Research Centre, which will consist of selected research groups led by the scientists at IOCB.
In 1991 and 1992, Gilead entered into license agreements with IOCB and the Rega Institute for Medical Research, Katholic University in Leuven, Belgium that cover a large number of nucleotide analogue compounds and structures.
Several of these nucleotide compounds discovered through a collaborative research effort between IOCB’s Dr Antonin Holy and Dr Erik DeClercq of the Rega Institute, were developed by Gilead, resulting in Vistide for the treatment of CMV retinitis in AIDS patients, Viread for the treatment of HIV infection and Hepsera for the treatment of chronic hepatitis B.
“The compounds that Gilead licensed from IOCB represent an important component of our product portfolio and, most importantly, have helped deliver new treatment options to hundreds of thousands of patients suffering from HIV and chronic hepatitis B,” said John Martin, president and CEO, Gilead Sciences.